Oxidative phosphorylation as an emerging target in cancer therapy
Cancer cells have upregulated glycolysis compared to normal cells, which has led many to the assumption that oxidative phosphorylation (OXPHOS) is downregulated in all cancers. However, recent studies have shown that OXPHOS can be also upregulated in certain cancers, including leukemias, lymphomas,...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Association for Cancer Research
2018
|
| _version_ | 1797088425757638656 |
|---|---|
| author | Ashton, T McKenna, W Kunz-Schughart, L Higgins, G |
| author_facet | Ashton, T McKenna, W Kunz-Schughart, L Higgins, G |
| author_sort | Ashton, T |
| collection | OXFORD |
| description | Cancer cells have upregulated glycolysis compared to normal cells, which has led many to the assumption that oxidative phosphorylation (OXPHOS) is downregulated in all cancers. However, recent studies have shown that OXPHOS can be also upregulated in certain cancers, including leukemias, lymphomas, pancreatic ductal adenocarcinoma, high OXPHOS subtype melanoma and endometrial carcinoma, and that this can occur even in the face of active glycolysis. OXPHOS inhibitors could therefore be used to target cancer subtypes in which OXPHOS is upregulated, and to alleviate therapeutically adverse tumor hypoxia. Several drugs including metformin, atovaquone and arsenic trioxide are used clinically for non-oncological indications, but emerging data demonstrates their potential use as OXPHOS inhibitors. We highlight novel applications of OXPHOS inhibitors with a suitable therapeutic index to target cancer cell metabolism. |
| first_indexed | 2024-03-07T02:49:54Z |
| format | Journal article |
| id | oxford-uuid:ad53fe47-0658-4591-b237-33264b482f86 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:49:54Z |
| publishDate | 2018 |
| publisher | American Association for Cancer Research |
| record_format | dspace |
| spelling | oxford-uuid:ad53fe47-0658-4591-b237-33264b482f862022-03-27T03:34:49ZOxidative phosphorylation as an emerging target in cancer therapyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ad53fe47-0658-4591-b237-33264b482f86EnglishSymplectic Elements at OxfordAmerican Association for Cancer Research2018Ashton, TMcKenna, WKunz-Schughart, LHiggins, GCancer cells have upregulated glycolysis compared to normal cells, which has led many to the assumption that oxidative phosphorylation (OXPHOS) is downregulated in all cancers. However, recent studies have shown that OXPHOS can be also upregulated in certain cancers, including leukemias, lymphomas, pancreatic ductal adenocarcinoma, high OXPHOS subtype melanoma and endometrial carcinoma, and that this can occur even in the face of active glycolysis. OXPHOS inhibitors could therefore be used to target cancer subtypes in which OXPHOS is upregulated, and to alleviate therapeutically adverse tumor hypoxia. Several drugs including metformin, atovaquone and arsenic trioxide are used clinically for non-oncological indications, but emerging data demonstrates their potential use as OXPHOS inhibitors. We highlight novel applications of OXPHOS inhibitors with a suitable therapeutic index to target cancer cell metabolism. |
| spellingShingle | Ashton, T McKenna, W Kunz-Schughart, L Higgins, G Oxidative phosphorylation as an emerging target in cancer therapy |
| title | Oxidative phosphorylation as an emerging target in cancer therapy |
| title_full | Oxidative phosphorylation as an emerging target in cancer therapy |
| title_fullStr | Oxidative phosphorylation as an emerging target in cancer therapy |
| title_full_unstemmed | Oxidative phosphorylation as an emerging target in cancer therapy |
| title_short | Oxidative phosphorylation as an emerging target in cancer therapy |
| title_sort | oxidative phosphorylation as an emerging target in cancer therapy |
| work_keys_str_mv | AT ashtont oxidativephosphorylationasanemergingtargetincancertherapy AT mckennaw oxidativephosphorylationasanemergingtargetincancertherapy AT kunzschughartl oxidativephosphorylationasanemergingtargetincancertherapy AT higginsg oxidativephosphorylationasanemergingtargetincancertherapy |